Myb proteins in life, death and differentiation

Current Opinion in Genetics and Development

Volumn 8, Issue 1, 1998, Pages 76-81

  Weston, Kathy ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; TRANSCRIPTION FACTOR;

APOPTOSIS; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION;

EID: 0031888616     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(98)80065-8     Document Type: Article

References (70)

1. Wolff L. Myb-induced transformation. Crit Rev Onc. 7:1996;245-260.
2. Lipsick J. One billion years of Myb. Oncogene. 13:1996;223-235.
3. Thompson MA, Ramsay RG. Myb: an old oncoprotein with new roles. Bioessays. 17:1995;341-350.
4. Latham K, Litvin J, Orth J, Patel B, Mettus R, Reddy E. Temporal patterns of A-myb and B-myb gene expression during testis development. Oncogene. 13:1996;1161-1168.
5. Kastan MB, Stone KD, Civin CI. Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells. Blood. 74:1989;1517-1524.
6. Sitzmann J, Noben-Trauth K, Klempnauer K. Expression of mouse c-myb during embryonic development. Oncogene. 11:1995;2273-2279.
7. 1 phase of the cell cycle. J Biol Chem. 264:1989;6990-6995.
8. Rosenthal M, Thompson M, Ellis S, Whitehead R, Ramsay R. Colonic expression of c-myb is initiated in utero and continues throughout adult life. Cell Growth Differ. 7:1996;961-967.
9. Mettus R, Litvin J, Wali A, Toscani A, Latham K, Hatton K, Reddy E. Murine A-myb: evidence for differential splicing and tissue-specific expression. Oncogene. 9:1994;3077-3086.
10. Trauth K, Mutschler B, Jenkins N, Gilbert D, Copeland N, Klempnauer K. Mouse A-myb encodes a trans-activator and is expressed in mitotically active cells of the developing central nervous system, adult testis and B lymphocytes. EMBO J. 13:1994;5994-6005.
11. Mucenski ML, McLain K, Kier AB, Swerdlow SH, Schreiner CM, Miller TA, Pietryga DW, Scott WJ Jr, Potter SS. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell. 65:1991;677-689.
12. Toscani A, Mettus R, Coupland R, Simpkins H, Litvin J, Orth J, Hatton K, Reddy E. Arrest of spermatogenesis and defective breast development in mice lacking A-myb. of special interest Nature. 386:1997;713-717 Demonstration that A-myb plays a critical role in spermatogenesis and mammary gland development. Spermatogenesis is blocked at the early pachytene stage. During pregnancy, hormone-induced ductal proliferation and morphogenesis in mammary glands does not occur.
13. Thompson CB, Challoner PB, Neiman PE, Groudine M. Expression of the c-myb proto-oncogene during cellular proliferation. Nature. 319:1986;374-380.
14. Lam E, Robinson C, Watson R. Characterization and cell cycle-regulated expression of mouse B-myb. Oncogene. 7:1992;1885-1890.
15. 1-to-S phase transition and cooperates with c-myc to mediate progression to S phase. of special interest Mol Cell Biol. 17:1997;2448-2457 The only demonstration that Myb proteins can drive resting cells into cycle. No cell death associated with c-Myc microinjection; suggests c-Myc and Mybs act respectively as competence and progression factors.
16. Bender TP, Thompson C, Kuehl WM. Differential expression of c-myb mRNA in murine B lymphomas by a block to transcription elongation. Science. 237:1987;1473-1476.
17. Blau J, Xiao H, McCracken S, O'Hare P, Greenblatt J, Bentley D. Three functional classes of transcriptional activation domains. Mol Cell Biol. 16:1996;2044-2055.
18. 1 progression and c-myb progression. Science. 233:1986;203-206.
19. Rohwer F, Todd S, McGuire K. The effect of IL-2 treatment on transcriptional attenuation in proto-oncogenes pim-1 and c-myb in human thymic blast cells. J Immunol. 157:1996;643-649.
20. Lam E, Watson R. An E2F-binding site mediates cell-cycle regulated repression of mouse B-myb transcription. EMBO J. 12:1993;2705-2713.
21. 1 but thereafter is empty.
22. Lam E, Morris J, Davies R, Crook T, Watson R, Vousden K. HPV16 E7 oncoprotein deregulates B-myb expression: correlation with targeting of p107/E2F complexes. EMBO J. 13:1994;871-878.
23. Bennett J, Farlie P, Watson R. E2F binding is required but not sufficient for repression of B-myb transcription in quiescent fibroblasts. Oncogene. 13:1996;1073-1082.
24. Liu N, Lucibello F, Zwicker J, Engeland K, Muller R. Cell cycle-regulated repression of B-myb transcription: cooperation of an E2F site with a contiguous corepressor element. Nucleic Acids Res. 24:1996;2905-2910.
25. Hurford RK, Cobrinik D, Lee M-H, Dyson N. pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. of outstanding interest Genes Dev. 11:1997;1447-1463 Analysis of 21 E2F target genes in mice lacking Rb or both p107 and p130. B-myb expression is unchanged in the former but is constitutive in the latter. Demonstrates unequivocally that the data gathered in vitro and in transfection experiments are completely correct!
26. Facchinetti V, Loffarelli L, Schreek S, Oelgeschlager M, Luscher B, Introna M, Golay J. Regulatory domains of the A-Myb transcription factor and its interaction with the CBP/p300 adaptor molecules. Biochem J. 324:(3):1997;729-736.
27. Lane S, Farlie P, Watson R. B-Myb function can be markedly enhanced by cyclin A-dependent kinase and protein truncation. of outstanding interest Oncogene. 14:1997;2445-2453 This and the following paper [28] lay to rest past controversy as to whether B-Myb activates transcription or not. Both papers show that the B-Myb transcription activation domain can be unmasked by losing the protein's carboxyl terminus, or by phosphorylating it.
28. Ziebold U, Bartsch O, Marais R, Ferrari S, Klempnauer K. Phosphorylation and activation of B-Myb by cyclin A-Cdk2. of outstanding interest Curr Biol. 7:1997;253-260 See annotation [27].
29. 1/S, giving further support to the idea that all Myb proteins are tightly regulated during the cell cycle.
30. Sala A, Kundu M, Casella I, Engelhard A, Calabretta B, Grasso L, Paggi M, Giordano A, Watson R, Khalili K, Peschle C. Activation of human B-MYB by cyclins. Proc Natl Acad Sci USA. 94:1997;532-536.
31. Aziz N, Miglarese M, Hendrickson R, Shabanowitz J, Sturgill T, Hunt D, Bender T. Modulation of c-Myb-induced transcription activation by a phosphorylation site near the negative regulatory domain. Proc Natl Acad Sci USA. 92:1995;6429-6433.
32. Taylor SJ, Shalloway D. Cell-cycle-dependent activation of Ras. Curr Biol. 6:1996;1621-1627.
33. Bies J, Wolff L. Oncogenic activation of c-Myb by carboxyl-terminal truncation leads to decreased proteolysis by the ubiquitin-26S proteasome pathway. Oncogene. 14:1997;203-212.
34. Dai P, Akimaru H, Tanaka Y, Hou D-X, Yasukawa T, Kanei-Ishii C, Takahashi T, Ishii S. CBP as a transcriptional coactivator of c-Myb. of special interest Genes Dev. 10:1996;528-540 This paper and the next [35] were the first to show that c-Myb could interact directly with another protein involved in transcription, and that this modulated the activity of c-Myb.
35. Oelgeschlager M, Janknecht R, Krieg J, Schreek S, Luscher B. Interaction of the co-activator CBP with Myb proteins: effects on Myb-specific transactivation and on the cooperativity with NF-M. of special interest EMBO J. 15:1996;2771-2780 See annotation [34].
36. Dash A, Orrico F, Ness S. The EVES motif mediates both intermolecular and intramolecular regulation of c-Myb. of outstanding interest Genes Dev. 10:1996;1858-1869 First demonstration of a protein interaction with the c-Myb negative regulatory domain which might affect c-Myb's activity. These observations may be the key to one aspect of c-Myb regulation.
37. Ebneth A, Schweers O, Thole H, Fagin U, Urbanke C, Maass G, Wolfes H. Biophysical characterization of the c-Myb DNA-binding domain. Biochemistry. 33:1994;14586-14593.
38. Fu S, Lipsick J. FAETL motif required for leukemic transformation by v-Myb. J Virol. 70:1996;5600-5610.
39. Kanei-Ishii C, MacMillan EM, Nomura T, Sarai A, Ramsay RG, Aimoto S, Ishii S, Gonda TJ. Transactivation and transformation by Myb are negatively regulated by a leucine-zipper structure. Proc Nat Acad Sci USA. 89:1992;3088-3092.
40. Nomura T, Sakai N, Sarai A, Sudo T, Kanei-Ishii C, Ramsay RG, Favier D, Gonda TJ, Ishii S. Negative autoregulation of c-Myb activity by homodimer formation through the leucine zipper. J Biol Chem. 268:1993;21914-21923.
41. Favier D, Gonda TJ. Detection of proteins that bind to the leucine zipper motif of c-Myb. Oncogene. 9:1994;305-311.
42. Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS, Kramer TB, et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA. 92:1995;4051-4055.
43. Jarvis T, Alby L, Beaudry A, Wincott F, Beigelman L, McSwiggen J, Usman N, Stinchcomb D. Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA. of special interest RNA. 2:1996;419-428 An interesting and well-controlled study suggesting an efficient and potentially very powerful method for inhibiting Myb activity. Nuclease-resistant ribozymes were constructed which specifically inhibited c-Myb mRNA production. The ribozymes were more active and exhibited fewer non-specific effects than did comparable antisense oligonucleotides.
44. 1 arrest. Gene. 182:1996;123-128.
45. Sala A, Casella I, Bellon T, Calabretta B, Watson R, Peschle C. B-myb promotes S phase and is a downstream target of the negative regulator p107 in human cells. J Biol Chem. 271:1996;9363-9367.
46. 1 arrest. Proc Natl Acad Sci USA. 91:1994;10079-10083.
47. DeRocco S, Iozzo R, Ma X, Schwarting R, Peterson D, Calabretta B. Ectopic expression of A-myb in transgenic mice causes follicular hyperplasia and enhanced B lymphocyte proliferation. Proc Natl Acad Sci USA. 94:1997;3240-3244.
48. Brandt T, Fraser D, Leal S, Halandras P, Kroll A, Kroll D. c-Myb trans-activates the human DNA topoisomerase llalpha gene promoter. J Biol Chem. 272:1997;6278-6284.
49. Miglarese M, Halaban R, Gibson NW. Regulation of FGF-2 expression in melanoma cells by the c-Myb proto-oncoprotein. Cell Growth Differ. 8:1997;1199-1210.
50. Melotti P, Calabretta B. Induction of hematopoietic commitment and erythromyeloid differentiation in embryonal stem cells constitutively expressing c-myb. Blood. 87:1996;2221-2234.
51. Hogg A, Schirm S, Nakagoshi H, Bartley P, Ishii S, Bishop JM, Gonda TJ. Inactivation of a c-Myb/estrogen receptor fusion protein in transformed primary cells leads to granulocyte/macrophage differentiation and down regulation of c-kit but not c-myc or cdc2. Oncogene. 15:1997;2885-2898.
52. Ness SA, Engel JD. Vintage reds and whites: combinatorial transcription factor utilization in hematopoietic differentiation. Curr Opin Genet Dev. 4:1994;718-724.
53. Shapiro LH. Myb and Ets proteins cooperate to transactivate an early myeloid gene. J Biol Chem. 270:1995;8763-8771.
54. Frampton J, Ramqvist T, Graf T. v-Myb of E26 leukemia virus up-regulates bcl-2 and suppresses apoptosis in myeloid cells. of outstanding interest Genes Dev. 10:1996;2720-2731 This paper and the next [55] show that Myb proteins are involved in protecting cells from apoptosis in two different organisms and haemopoietic lineages. Convincing evidence is provided that bcl-2 is a bona fide target gene for Myb proteins and it is speculated that it may also be involved in oncogenic transformation by v-Myb.
55. Taylor D, Badiani P, Weston K. A dominant interfering Myb mutant causes apoptosis in T cells. of outstanding interest Genes Dev. 10:1996;2732-2744 See annotation [54].
56. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell. 75:1993;229-240.
57. Salomoni P, Perrotti D, Martinez R, Franceschi C, Calabretta B. Resistance to apoptosis in CTLL-2 cells constitutively expressing c-Myb is associated with induction of BCL-2 expression and Myb-dependent regulation of bcl-2 promoter activity. Proc Natl Acad Sci USA. 94:1997;3296-3301.
58. Selvakumaran M, Lin HK, Sjin RT, Reed JC, Liebermann DA, Hoffman B. The novel primary response gene MyD118 and the proto-oncogenes myb, myc, and bcl-2 modulate transforming growth factor beta 1-induced apoptosis of myeloid leukemia cells. Mol Cell Biol. 14:1994;2352-2360.
59. Bies J, Wolff L. Acceleration of apoptosis in transforming growth factor beta 1-treated M1 cells ectopically expressing B-myb. Cancer Res. 55:1995;501-504.
60. Sala A, Casella I, Grasso L, Bellon T, Reed J, Miyashita T, Peschle C. Apoptotic response to oncogenic stimuli: cooperative and antagonistic interactions between c-myb and the growth suppressor p53. Cancer Res. 56:1996;1991-1996.
61. Melotti P, Ku DH, Calabretta B. Regulation of the expression of the hematopoietic stem cell antigen CD34: role of c-myb. J Exp Med. 179:1994;1023-1028.
62. Britos-Bray M, Friedman AD. Core binding factor cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-Myb. Mol Cell Biol. 17:1997;5127-5135.
63. Nuchprayoon I, Simkevich C, Luo M, Friedman A, Rosmarin A. GABP cooperates with c-Myb and C/EBP to activate the neutrophil elastase promoter. Blood. 89:1997;4546-4554.
64. Burk O, Klempnauer KH. Estrogen-dependent alterations in differentiation state of myeloid cells caused by a v-myb/estrogen receptor fusion protein. EMBO J. 10:1991;3713-3719.
65. Ness SA, Kowenz-Leutz E, Casini T, Graf T, Leutz A. Myb and NFM: combinatorial activators of myeloid genes in heterologous cell types. Genes Dev. 7:1993;749-759.
66. Burk O, Worpenberg S, Haenig B, Klempnauer K-H. tom-1, a novel v-Myb target gene expressed in AMV- and E26-transformed myelomonocytic cells. EMBO J. 16:1997;1371-1380.
67. McCracken S, Leung S, Bosselut R, Ghysdael J, Miyamoto NG. Myb and Ets related transcription factors are required for activity of the human lck type I promoter. Oncogene. 9:1994;3609-3615.
68. Ess KC, Whitaker TL, Cost GJ, Witte DP, Hutton JJ, Aronow BJ. A central role for a single c-Myb binding site in a thymic locus control region. Mol Cell Biol. 15:1995;5707-5715.
69. Hernandez-Munain C, Lauzurica P, Krangel M. Regulation of T cell receptor delta gene rearrangement by c-Myb. J Exp Med. 183:1996;289-293.
70. Leverson JD, Ness SA. Point mutations in v-Myb disrupt a cyclophilin-catalyzed negative regulatory element. Mol Cell. 1:1998;203-211.